Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 8, 2008, Pages 1413-1421

  Hamad, O A ^a   Ekdahl, K N ^a,b   Nilsson, P H ^b   Andersson, J ^a   Magotti, P ^c   Lambris, J D ^c   Nilsson, Boo ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LINNAEUS UNIVERSITY   (Sweden)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chondroitin sulfate; Coagulation; Complement; Platelets; Thrombin receptor activating peptide (TRAP)

Indexed keywords

CD11B ANTIGEN; CHONDROITIN ABC LYASE; CHONDROITIN SULFATE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPSTATIN; LEPIRUDIN; RECEPTOR ANTIBODY; STATIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6;

ANTIGEN EXPRESSION; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKOCYTE FUNCTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE RICH PLASMA;

BLOOD PLATELETS; CHONDROITIN SULFATES; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; GRANULOCYTES; HUMANS; MONOCYTES; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; RECEPTORS, THROMBIN;

EID: 47649090540     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03034.x     Document Type: Article

References (43)

1. Palikhe A, Sinisalo J, Seppanen M, Haario H, Meri S, Valtonen V, Nieminen MS, Lokki ML. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol 2007; 99: 890-5.
2. Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, Rovinetti C, Descovich GC, Puddu P. Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995; 98: 357-64.
3. Iltumur K, Karabulut A, Toprak G, Toprak N. Complement activation in acute coronary syndromes. APMIS 2005; 113: 167-74.
4. Langlois PF, Gawryl MS. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis 1988; 70: 95-105.
5. Yasuda M, Kawarabayashi T, Akioka K, Teragaki M, Oku H, Kanayama Y, Takeuchi K, Takeda T, Kawase Y, Ikuno Y. The complement system in the acute phase of myocardial infarction. Jpn Circ J 1989; 53: 1017-22.
6. Yasuda M, Takeuchi K, Hiruma M, Iida H, Tahara A, Itagane H, Toda I, Akioka K, Teragaki M, Oku H. The complement system in ischemic heart disease. Circulation 1990; 81: 156-63.
7. Markiewski MM, Nilsson B, Nilsson Ekdahl K, Mollnes TE, Lambris JD. Complement and coagulation: Strangers or partners in crime? Trends Immunol 2007; 28: 184-92.
8. Cicardi M, Zingale L, Zanichelli A, Pappalardo E, Cicardi B. C1 inhibitor: Molecular and clinical aspects. Springer Semin Immunopathol 2005; 27: 286-98.
9. Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 1981; 153: 665-76.
10. Spath P, Gabl F. Critical role of the conversion of the third complement component C3 (beta 1C/beta 1A) for its immunochemical quantitation. Clin Chim Acta 1976; 73: 171-5.
11. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA. Generation of C5a in the absence of C3: A new complement activation pathway. Nat Med 2006; 12: 682-7.
12. Sims PJ, Wiedmer T. The response of human platelets to activated components of the complement system. Immunol Today 1991; 12: 338-42.
13. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77: 394-8.
14. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, Rafail S, Kartalis G, Sideras P, Lambris JD. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006; 177: 4794-802.
15. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997; 185: 1619-27.
16. Kalowski S, Howes EL Jr, Margaretten W, McKay DG. Effects of intravascular clotting on the activation of the complement system: The role of the platelet. Am J Pathol 1975; 78: 525-36.
17. Del Conde I, Cruz MA, Zhang H, Lopez JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201: 871-9.
18. Peerschke EI, Yin W, Grigg SE, Ghebrehiwet B. Blood platelets activate the classical pathway of human complement. J Thromb Haemost 2006; 4: 2035-42.
19. Ward JV, Packham MA. Characterization of the sulfated glycosaminoglycan on the surface and in the storage granules of rabbit platelets. Biochim Biophys Acta 1979; 583: 196-207.
20. Okayama M, Oguri K, Fujiwara Y, Nakanishi H, Yonekura H, Kondo T, Ui N. Purification and characterization of human platelet proteoglycan. Biochem J 1986; 233: 73-81.
21. Donato JL, Nogueira MD, Marcondes S, Antunes E, Nader HB, Dietrich CP, de Nucci G. The kinetics of chondroitin 4-sulfate release from stimulated platelets and its relation to thromboxane A2 formation and granule secretion. Braz J Med Biol Res 1994; 27: 2163-7.
22. Silvestri L, Baker JR, Roden L, Stroud RM. The C1q inhibitor in serum is a chondroitin 4-sulfate proteoglycan. J Biol Chem 1981; 256: 7383-7.
23. Ghebrehiwet B, Galanakis DK. C1q inhibitor (chondroitin-4-sulfate proteoglycan): Structure and function. Behring Inst Mitt 1993; 93: 214-23.
24. Katragadda M, Magotti P, Sfyroera G, Lambris JD. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem 2006; 49: 4616-22.
25. Christensen K, Larsson R, Emanuelsson H, Elgue G, Larsson A. Coagulation and complement activation. Biomaterials 2001; 22: 349-55.
26. Mollnes TE, Lea T, Froland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985; 22: 197-202.
27. Tenner AJ, Lesavre PH, Cooper NR. Purification and radiolabeling of human C1q. J Immunol 1981; 127: 648-53.
28. Sjoholm AG, Selander B, Ostenson S, Holmstrom E, Soderstrom C. Normal human serum depleted of C1q, factor D and properdin: Its use in studies of complement activation. APMIS 1991; 99: 1120-8.
29. Nilsson UR, Larm O, Nilsson B, Storm KE, Elwing H, Nilsson Ekdahl K. Modification of the complement binding properties of polystyrene: effects of end-point heparin attachment. Scand J Immunol 1993; 37: 349-54.
30. Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE, Lambris JD. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 2003; 198: 913-23.
31. Hong J, Larsson A, Ekdahl KN, Elgue G, Larsson R, Nilsson B. Contact between a polymer and whole blood: Sequence of events leading to thrombin generation. J Lab Clin Med 2001; 138: 139-45.
32. Nilsson B, Larsson R, Hong J, Elgue G, Ekdahl KN, Sahu A, Lambris JD. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 1998; 92: 1661-7.
33. Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, Videm V, Lappegard KT, Kohl J, Lambris JD. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002; 100: 1869-77.
34. Kirschfink M, Blase L, Engelmann S, Schwartz-Albiez R. Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1. J Immunol 1997; 158: 1324-31.
35. Makatsori E, Karamanos NK, Papadogiannakis N, Hjerpe A, Anastassiou ED, Tsegenidis T. Synthesis and distribution of glycosaminoglycans in human leukemic B- and T-cells and monocytes studied using specific enzymic treatments and high-performance liquid chromatography. Biomed Chromatogr 2001; 15: 413-17.
36. Kolset SO, Tveit H. Serglycin -structure and biology. Cell Mol Life Sci 2008; 65: 1073-85.
37. Goel MS, Diamond SL. Neutrophil enhancement of fibrin deposition under flow through platelet-dependent and -independent mechanisms. Arterioscler Thromb Vasc Biol 2001; 21: 2093-8.
38. Gross TJ, Leavell KJ, Peterson MW. CD11b/CD18 mediates the neutrophil chemotactic activity of fibrin degradation product D domain. Thromb Haemost 1997; 77: 894-900.
39. Kolev K, Komorowicz E, Owen WG, Machovich R. Quantitative comparison of fibrin degradation with plasmin, miniplasmin, neutrophil leukocyte elastase and cathepsin G. Thromb Haemost 1996; 75: 140-6.
40. Simon DI, Ezratty AM, Francis SA, Rennke H, Loscalzo J. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): A nonplasmin fibrinolytic pathway. Blood 1993; 82: 2414-22.
41. Taylor FB Jr, Muller-Eberhard HJ. Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets. J Clin Invest 1970; 49: 2068-85.
42. Mocco J, Wilson DA, Komotar RJ, Sughrue ME, Coates K, Sacco RL, Elkind MS, Connolly ES Jr. Alterations in plasma complement levels after human ischemic stroke. Neurosurgery 2006; 59: 28-33.
43. Ekdahl KN, Bengtsson AA, Andersson J, Elgue G, Ronnblom L, Sturfelt G, Nilsson B. Thrombotic disease in systemic lupus erythematosus is associated with a maintained systemic platelet activation. Br J Haematol 2004; 125: 74-8.